California-based Foresite Capital Management VI sold 585,000 shares of Edgewise Therapeutics in the third quarter. The overall position value fell by about $7.67 million from the previous period. The ...
Discover why Edgewise Therapeutics, Inc. is rated Buy amid strong trial data, unique HCM treatment, and major 2026 catalysts. Click for this EWTX update.
As of Wednesday, December 24, Edgewise Therapeutics, Inc.’s EWTX share price has surged by 20.17%, which has investors questioning if this is right time to sell.
Italfarmaco S.p.A. and JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR"), today announced an exclusive licensing agreement for the development and commercialisation of givinostat in Japan. Under the ...
The US HHS has added Duchenne muscular dystrophy and metachromatic leukodystrophy to newborn screening, citing benefits of early detection and access to FDA-approved treatments.
HHS has announced the addition of Duchenne muscular dystrophy and metachromatic leukodystrophy to the Recommended Uniform ...
Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy December 17, ...
The Recommended Uniform Screening Panel now includes DMD and MLD, which has implications for firms developing treatments for ...
U.S. Health Secretary Robert F. Kennedy Jr. on Tuesday added two rare genetic disorders, Duchenne Muscular Dystrophy and ...
Health secretary Robert F. Kennedy Jr. on Tuesday added two deadly rare diseases, Duchenne muscular dystrophy and ...
In 2024, Becker’s reported on 11 academic health centers that had opened or were developing new ASCs and outpatient centers. In 2025, that number increased to 14, a move that reflects growing interest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback